H3K28ac Antibodies

Target Information

H3K28ac refers to acetylation of lysine 28 on histone H3, a post translational modification catalyzed by histone acetyltransferases (HATs) and reversed by histone deacetylases (HDACs). This acetylation reduces the positive charge on the lysine residue, weakening histone DNA interactions and promoting a more open chromatin structure that facilitates access of transcription factors and RNA polymerase, thereby supporting transcriptional activation. Biologically, H3K28ac is enriched at promoters and enhancers of actively transcribed genes and serves as a marker of regulatory regions involved in gene expression, cellular differentiation, development, and responses to environmental signals. Clinically, abnormal H3K28ac patterns are associated with diseases such as cancer, where dysregulated acetylation contributes to altered gene expression, making H3K28ac a potential biomarker and positioning HATs and HDACs as therapeutic targets, with inhibitors under investigation for treating acetylation related disorders.